Precision medicine in KCNJ11 permanent neonatal diabetes
- PMID: 29880307
- PMCID: PMC6345272
- DOI: 10.1016/S2213-8587(18)30138-4
Precision medicine in KCNJ11 permanent neonatal diabetes
Conflict of interest statement
We declare no competing interests.
Comment on
-
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.Lancet Diabetes Endocrinol. 2018 Aug;6(8):637-646. doi: 10.1016/S2213-8587(18)30106-2. Epub 2018 Jun 4. Lancet Diabetes Endocrinol. 2018. PMID: 29880308 Free PMC article.
References
-
- Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N EnglJ Med 2004; 350: 1838–49. - PubMed
-
- Bowman P, Sulen A, Barbetti F, et al. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol 2018; published online June 1 10.1016/S2213- 8587(18)30106–2. - DOI - PMC - PubMed
-
- Riddle MC. Modern sulfonylureas: dangerous or wrongly accused? Diabetes Care 2017; 40: 629–31. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical